血尿胶囊抗慢性肾炎机制的网络药理学研究及实验验证OA
Network Pharmacology Study and Experimental Validation on the Mechanism of Xueniao Capsules in Ameliorating Chronic Glomerulonephritis
综合运用网络药理学、分子对接、虚拟氨基酸定点突变及实验验证,系统分析血尿胶囊治疗慢性肾炎(Chronic Glomerulonephritis,CG)的作用机制.基于中药系统药理学数据库与分析平台(Traditional Chinese Medi-cine Systems Pharmacology Database and Analysis Platform,TCMSP)和中医药百科全书数据库(The Encyclopedia of Traditional Chinese Medicine,ETCM)筛选血尿胶囊活性成分及靶点,结合GeneCards数据库和在线人类孟德尔遗传数据库(Online Mendelian Inheritance in Man,OMIM)获取CG疾病靶点,取交集得到共同靶点.利用蛋白互作数据库(Search Tool for the Retrieval of Interacting Genes/Proteins,STRING)和Cytoscape构建成分-靶点网络和蛋白质相互作用(Protein-Protein Interaction Networks,PPI)网络,并进行拓扑分析.通过R Studio对共有靶点进行基因本体(Gene Ontology,GO)功能富集分析及京都基因与基因组百科全书(Kyoto Encyclopedia of Genes and Genomes,KEGG)通路富集分析;对核心靶点与成分进行分子对接与丙氨酸扫描突变验证;采用CCK-8法和Western blot分别评估细胞活性与蛋白表达.共筛选出血尿胶囊8个核心活性成分(包括槲皮素、山柰酚、汉黄芩素等)和53个共同靶点(PTGS2、MMP9、PPARG、HSP90AA1、AKT1、VEGFA等).GO分析表明,其作用与调控儿茶酚胺结合、G蛋白偶联胺受体活性等分子功能有关,可能通过抑制免疫过度活化及炎症因子释放起效.KEGG分析提示,血尿胶囊主要调控PI3K/Akt、IL-17和AGE-RAGE信号通路,其中抑制PI3K/Akt通路可能是其改善慢性肾炎表型的关键机制.
The mechanism of action of Xueniao Capsules in treating Chronic Glomerulonephritis(CG)was systematically investigat-ed by integrating multiple artificial intelligence technologies—including bioinformatics data analysis,network pharmacology,molec-ular docking,and virtual amino acid site-directed mutation—and combining them with experimental validation.Active components and potential targets of Xueniao Capsules were screened using the Traditional Chinese Medicine Systems Pharmacology Database and Analysis Platform(TCMSP)and The Encyclopedia of Traditional Chinese Medicine(ETCM)databases.CG-related targets were extracted from GeneCards and Online Mendelian Inheritance in Man(OMIM)databases,and the common interaction targets were yielded by intersection of these two sets.A compound-component-target interaction network was constructed using the search tool for the retrieval of interacting genes/proteins(STRING)database and Cytoscape software.The protein-protein interaction(PPI)and network topology analysis on the obtained intersection targets were performed.Gene Ontology(GO)functional annotation and KEGG pathway enrichment analysis on shared targets were performed using R Studio and relevant toolkits.Further validation on core targets and compound components was performed through network analysis via molecular docking and alanine scan mutation studies.Xueniao Capsules cytotoxicity and cellular activity were assessed using the CCK-8 assay,and key predictions were experi-mentally validated via Western blot analysis.8 key active components and 53 shared targets were identified for Xueniao Capsules in treating CG.The primary active components include quercetin,kaempferol,baicalin,coix seed ester,stigmasterol,sitosterol,resvera-trol,colchicine,and myristic acid;Core targets include PTGS2,MMP9,PPARG,HSP90AA1,AKT1,and VEGFA.GO analysis sug-gests that Xueniao Capsules may exert therapeutic effects against CG by synergistically inhibiting excessive immune responses and inflammatory factor release through regulating molecular functions such as catecholamine binding,G protein-coupled amine recep-tor activity,ammonium ion binding,and neurotransmitter receptor activity.KEGG pathway analysis revealed that Xueniao Capsules primarily regulate signaling pathways including PI3K/Akt,IL-17,and AGE/RAGE.Among these,inhibition of the PI3K/Akt signal-ing pathway represents a key mechanism for improving the pathological phenotype of chronic nephritis.
卢白荟;李静
中南民族大学 药学院,湖北 武汉 430074中南民族大学 药学院,湖北 武汉 430074
医药卫生
血尿胶囊慢性肾炎分子对接虚拟氨基酸定点突变PI3K/Akt信号通路
Xueniao capsuleschronic glomerulonephritismolecular dockingcomputational mutagenesisPI3K/Akt signaling path-way
《山西大学学报(自然科学版)》 2026 (5)
705-720,16
国家自然科学基金(82404451)中南民族大学中央高校基本科研业务费专项资金(CZQ24025CZH25030YZY25002)中央高校中南民族大学拔尖研究生科研项目(3212025yjshq053)
评论